Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01675479 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A NA study of Hyperopia, sponsored by Abbott Medical Optics.
- Completed
- Registry status
- NA
- Development phase
- 167
- Enrollment target
- 9
- Study locations
NCT01675479: Completed NA study of Hyperopia, sponsored by Abbott Medical Optics.
NCT01675479 is a NA study of Hyperopia that has completed, run by Abbott Medical Optics. The registered enrollment target is 167 participants, above the 108-participant average among 10 other Hyperopia trials with a reported enrollment target (55% higher). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01675479, a NA study of Hyperopia, has completed, sponsored by Abbott Medical Optics.
- COMPLETED
- Registry status
- NA
- Development phase
- 167 participants
- Enrollment target
- 9
- Study locations
Study Summary
Demonstrate that wavefront-guided LASIK using measurements from the iDesign System is safe and effective for the treatment of Hyperopia.
Primary Outcome
Hypothesis: \<5% of eyes will have a loss of \> 2 lines of BSCVA at any postoperative visit, as measured using ETDRS logMAR visual acuity charts at 4 meters
Conditions Studied
Interventions
- DEVICE LASIK correction of hyperopic refractive errors
Study Locations (9)
Missouri
- Pepose Vision Institute - Chesterfield
- Durrie Vision - Kansas City
California
- Maloney Vision Institute - Los Angeles
Florida
- University of Miami Bascom Palmer Eye Institute - Miami
Illinois
- Kraff Eye Institute - Chicago
New Mexico
- Coleman Vision - Albuquerque
Texas
- Lehmann Eye Center - Nacogdoches
Virginia
- The Eye Center - Fairfax
Washington
- King LASIK - Renton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2012-12-31 |
| Est. Completion | 2016-10-31 |
| Phase | NA |
What the finished NCT01675479 record still lists
NCT01675479 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, above the 108-participant average among 10 other Hyperopia trials with a reported enrollment target (55% higher).
The record links to 1 condition, with Hyperopia appearing as the primary indexed condition, and to 1 intervention - of which LASIK correction of hyperopic refractive errors is the first listed.
NCT01675479 lists 9 locations in 8 states (Missouri, California, Florida).
Frequently Asked Questions
What is clinical trial NCT01675479 about?
NCT01675479 is a clinical study titled "Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors". Demonstrate that wavefront-guided LASIK using measurements from the iDesign System is safe and effective for the treatment of Hyperopia.
What is the current status of trial NCT01675479?
This trial is currently completed. It is a NA study. The enrollment target is 167 participants. The study started on 2012-12-31. Estimated completion is 2016-10-31.
What conditions does trial NCT01675479 study?
This clinical trial studies the following conditions: Hyperopia.
What interventions are being tested in trial NCT01675479?
The interventions under investigation include: LASIK correction of hyperopic refractive errors (DEVICE).
Who is sponsoring clinical trial NCT01675479?
This trial is sponsored by Abbott Medical Optics, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01675479 being conducted?
This trial has 9 study locations across California, Florida, Illinois, Missouri, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hyperopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01675479's enrollment target sits among peer trials
167 3rd of 10 higher than 8 of 10 other Hyperopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hyperopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
A Clinical Comparison of Proclear® 1 Day Multifocal and Clariti® 1 Day Multifocal 3 Add
RECRUITING · NA
-
Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism
ACTIVE NOT RECRUITING · NA
-
Hyperopia Treatment Study 1 (HTS1) - Glasses vs Observation
COMPLETED · NA
-
Clinical Investigation of the WaveLight® EX500 Excimer Laser
COMPLETED · NA
-
A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI